<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01145014</url>
  </required_header>
  <id_info>
    <org_study_id>1284.1</org_study_id>
    <secondary_id>2009-015995-90</secondary_id>
    <nct_id>NCT01145014</nct_id>
  </id_info>
  <brief_title>To Investigate Safety, Tolerability, and Pharmacokinetics of Treatment With BI 660848 Rising Single Doses (From 2 mg to 600 mg) Administered as Oral Drinking Solution (Powder in Bottle).</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Phase I - Study to a) Assess Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses 2 mg to 600 mg of BI 660848 Administered as Oral Drinking Solution (Powder in Bottle) in Healthy Male Volunteers, b) to Explore the Relative Oral Bioavailability of an Immediate Release Tablet Formulation and c) to Assess the Impact of a High Fat Meal on the Oral Bioavailability of the Oral Drinking Solution (Powder in Bottle).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      As a transition from preclinical investigations to clinical development in this
      first-in-human trial, safety, tolerability, and pharmacokinetics of BI 660848 will be
      assessed in human male volunteers using single rising oral doses in order to provide the
      basis for a potential ongoing clinical development of BI 660848 in the indication of
      neuropathic pain.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>May 2010</start_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability (number and intensity of adverse events).</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in blood pressure.</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in pulse rate.</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in respiratory rate.</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in 12-lead ECG.</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in clinical laboratory test parameters.</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to maximum measured concentration)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (terminal half-life of the analyte in plasma)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT (mean residence time of the analyte in the body after drug intake)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (apparent clearance of the analyte in plasma after extravascular administration)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (apparent volume of distribution during the terminal phase following an extravascular dose)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aet1-t2 (amount of analyte eliminated in urine from the time point t1 to time point t2)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fet1-t2 (fraction of analyte eliminated in urine from the time point t1 to time point t2)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL R,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Pain</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 660848 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral drinking solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 660848 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral drinking solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 660848 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral drinking solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 660848 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral drinking solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 660848 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral drinking solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 660848 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral drinking solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 660848 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral drinking solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 660848 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral drinking solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 660848 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral drinking solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 660848 10,0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>immediate release tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 660848 50,0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>immediate release tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>matching placebo (oral drinking solution and IR tablets)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 660848</intervention_name>
    <description>2 mg oral drinking solution</description>
    <arm_group_label>BI 660848 2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 660848</intervention_name>
    <description>10 mg oral drinking solution</description>
    <arm_group_label>BI 660848 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 660848</intervention_name>
    <description>20 mg oral drinking solution</description>
    <arm_group_label>BI 660848 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 660848</intervention_name>
    <description>50 mg oral drinking solution</description>
    <arm_group_label>BI 660848 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 660848</intervention_name>
    <description>100 mg oral drinking solution</description>
    <arm_group_label>BI 660848 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 660848</intervention_name>
    <description>150 mg oral drinking solution</description>
    <arm_group_label>BI 660848 150 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 660848</intervention_name>
    <description>200 mg oral drinking solution</description>
    <arm_group_label>BI 660848 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 660848</intervention_name>
    <description>400 mg oral drinking solution</description>
    <arm_group_label>BI 660848 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 660848</intervention_name>
    <description>600 mg oral drinking solution</description>
    <arm_group_label>BI 660848 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 660848</intervention_name>
    <description>10,0 mg immediate release tablet</description>
    <arm_group_label>BI 660848 10,0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 660848</intervention_name>
    <description>50,0 mg immediate release tablet</description>
    <arm_group_label>BI 660848 50,0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo (oral drinking solution and IR tablets)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Healthy male based upon a complete medical history, including the physical
             examination, regarding vital signs (BP, PR), 12 lead ECG measurement, and clinical
             laboratory tests. There is no finding deviating from normal and of clinical relevance.
             There is no evidence of a clinically relevant concomitant disease.

          2. Age 21 and 50 years

          3. BMI 18.5 and &lt;30 kg/m2 (Body Mass Index)

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and the local legislation

        Exclusion criteria

          1. Any finding of the medical examination (including BP, PR, and ECG measurements)
             deviating from normal and of clinical relevance

          2. Evidence of a clinically relevant concomitant disease

          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          5. History of relevant orthostatic hypotension, fainting spells or blackouts

          6. Chronic or relevant acute infections

          7. History of relevant allergy/hypersensitivity (including allergy to the drug or its
             excipients) as judged clinically relevant by the investigator

          8. Intake of drugs with a long half-life (24 hours) within at least 1 month or less than
             10 half-lives of the respective drug prior to randomisation

          9. Use of drugs which might reasonably influence the results of the trial based on the
             knowledge at the time of protocol preparation within 10 days prior to randomisation

         10. Participation in another trial with an investigational drug within 2 months prior to
             randomisation

         11. Smoker (&gt;10 cigarettes or &gt;3 cigars or &gt;3 pipes/day)

         12. Inability to refrain from smoking on trial days as judged by the investigator

         13. Alcohol abuse (more than 30 g alcohol a day)

         14. Drug abuse

         15. Blood donation (more than 100 mL blood within 4 weeks prior to randomisation or during
             the trial)

         16. Excessive physical activities within 1 week prior to randomisation or during the trial

         17. Any laboratory value outside the reference range that is of clinical relevance

         18. Inability to comply with dietary regimen of the study centre
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1284.1.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ingelheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2010</study_first_submitted>
  <study_first_submitted_qc>June 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2010</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

